CLEVELAND, March 10 (UPI) -- U.S. researchers are testing the drug LibiGel to see if it will safely boost the libido of post-menopausal women.
The drug is a gel formulation of testosterone that delivers the hormone to the bloodstream through a once-daily application on the upper arm. It is designed to treat hypoactive sexual desire disorder, a common affliction for women who are past menopause, the Cleveland Plain Dealer reported Tuesday.
BioSante Pharmaceuticals Inc. launched the third phase of its clinical trials last year at more than 100 study sites. CEO Stephen Simes said he wants to submit an application to the U.S. Food and Drug Administration in 2010.
The company said a Phase II clinical trial showed LibiGel significantly increased the number of satisfying sexual events by 238 percent.
